Back to top
more

Halozyme Therapeutics (HALO)

(Delayed Data from NSDQ)

$68.98 USD

68.98
2,657,037

-2.71 (-3.78%)

Updated Oct 3, 2025 04:00 PM ET

After-Market: $69.00 +0.02 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.81%
2Buy17.98%
3Hold9.90%
4Sell5.43%
5Strong Sell2.74%
S&P50011.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Halozyme Therapeutics (HALO) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Halozyme Therapeutics (HALO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 8.62% and 4.93%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Ahan Chakraborty headshot

Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?

by Ahan Chakraborty

Let's look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week.

Zacks Equity Research

HALO Gears Up to Report Q4 Earnings: Here's What You Should Know

by Zacks Equity Research

Halozyme's fourth-quarter earnings are likely to have gained from higher royalty payments and revenues from collaboration agreements for its Enhanze technology.

Zacks Equity Research

Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Here's How Much You'd Have If You Invested $1000 in Halozyme Therapeutics a Decade Ago

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Zacks Equity Research

Qiagen (QGEN) Q4 Earnings Lag Estimates

by Zacks Equity Research

Qiagen (QGEN) delivered earnings and revenue surprises of -1.61% and 0.09%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Zacks Equity Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines

by Zacks Equity Research

Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines have been highlighted in this Industry Outlook article.

Zacks Equity Research

Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy

by Zacks Equity Research

BPMC stock rallies 18% on the company's optimistic 2025 outlook encompassing Ayvakit sales growth and pipeline progress.

Ekta Bagri headshot

5 Biotech Stocks Worth Adding to Your Portfolio in 2025

by Ekta Bagri

New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid pipeline progress position INCY, BMRN, EXEL, HALO and BPMC well in this volatile sector.

Zacks Equity Research

PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales

by Zacks Equity Research

Pacira stock gains 11% on better-than-expected preliminary Q4 sales figures. It also shares a strategic growth plan to drive innovation and value creation by 2030.

Zacks Equity Research

Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data

by Zacks Equity Research

Sana stock soars in a week following positive initial data from a first-in-human study of investigational cell therapy, UP421, in diabetes patients.

Zacks Equity Research

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

HALO Raises 2025 Financial Guidance, Keeps 2024 View, Stock Up

by Zacks Equity Research

Halozyme reiterates full-year 2024 financial guidance and raises its financial outlook for 2025. Shares rise.

Zacks Equity Research

DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation

by Zacks Equity Research

Denali obtains Breakthrough Therapy Designation for its experimental candidate, tividenofusp alfa (DNL310), for the treatment of pateints with Hunter syndrome.

Zacks Equity Research

NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to Buy

by Zacks Equity Research

Novo Nordisk stock gains 3% as analysts at UBS upgrade the company's rating from Neutral to Buy based on strong brand recognition of Ozempic and Wegovy.

Zacks Equity Research

CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva

by Zacks Equity Research

Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United States till Feb. 25, 2035.

Zacks Equity Research

Are Options Traders Betting on a Big Move in Halozyme (HALO) Stock?

by Zacks Equity Research

Investors need to pay close attention to Halozyme (HALO) stock based on the movements in the options market lately.